213 related articles for article (PubMed ID: 33309691)
21. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
23. [Role of VEGF in diseases of the retina].
Barquet LA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
[TBL] [Abstract][Full Text] [Related]
24. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
25. Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography.
Min JK; Lee S; Park JH; Woo JM; Yang HS
Acta Ophthalmol; 2018 Jun; 96(4):e546-e547. PubMed ID: 29068524
[No Abstract] [Full Text] [Related]
26. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
27. Targeting Angiogenesis in Colorectal Carcinoma.
Lopez A; Harada K; Vasilakopoulou M; Shanbhag N; Ajani JA
Drugs; 2019 Jan; 79(1):63-74. PubMed ID: 30617958
[TBL] [Abstract][Full Text] [Related]
28. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE
Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994
[TBL] [Abstract][Full Text] [Related]
29. Anti-VEGF Therapy for Retinal Vein Occlusions.
Campa C; Alivernini G; Bolletta E; Parodi MB; Perri P
Curr Drug Targets; 2016; 17(3):328-36. PubMed ID: 26073857
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC
PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018
[TBL] [Abstract][Full Text] [Related]
31. The role of Aflibercept in the management of age-related macular degeneration.
Hassan M; Afridi R; Sadiq MA; Soliman MK; Agarwal A; Sepah YJ; Do DV; Nguyen QD
Expert Opin Biol Ther; 2016; 16(5):699-709. PubMed ID: 26982640
[TBL] [Abstract][Full Text] [Related]
32. Ranibizumab for myopic choroidal neovascularization.
Ng DSC; Fung NSK; Yip FLT; Lai TYY
Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration.
Ringeisen AL; Parke DW; Dev S
Int Ophthalmol Clin; 2019; 59(1):127-135. PubMed ID: 30585922
[No Abstract] [Full Text] [Related]
34. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology.
Bakri SJ; Thorne JE; Ho AC; Ehlers JP; Schoenberger SD; Yeh S; Kim SJ
Ophthalmology; 2019 Jan; 126(1):55-63. PubMed ID: 30077616
[TBL] [Abstract][Full Text] [Related]
37. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
Freund KB; Korobelnik JF; Devenyi R; Framme C; Galic J; Herbert E; Hoerauf H; Lanzetta P; Michels S; Mitchell P; Monés J; Regillo C; Tadayoni R; Talks J; Wolf S
Retina; 2015 Aug; 35(8):1489-506. PubMed ID: 26076215
[TBL] [Abstract][Full Text] [Related]
38. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
39. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Eadie JA; Ip MS; Kulkarni AD
Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
[TBL] [Abstract][Full Text] [Related]
40. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
